Payment overview · 2025
General Payments
$331.49
16 reported records · 9 companies
Healthcare provider profile · identity verified
Imad Khdair, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SYLACAUGA, AL · NPI 1093725624
Verified facts
What the public records show
CMS Open Payments records show Imad Khdair, MD received $331.49 in general payments during 2025 across 16 reported records.
Corcept Therapeutics accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Trelegy Ellipta.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.91 | 21.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $66.79 | 20.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.82 | 16.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.40 | 15.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.35 | 6.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.11 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.74 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.92 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.45 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.49 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.91 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $66.79 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.82 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 389 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 198 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
198 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
389 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 811 | 244 |
| Atorvastatin Calcium | Atorvastatin Calcium | 793 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 654 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 565 | 163 |
| Mounjaro | Tirzepatide | 523 | 82 |
| Gabapentin | Gabapentin | 518 | 121 |
| Carvedilol | Carvedilol | 475 | 134 |
| Fluticasone Propionate | Fluticasone Propionate | 449 | 167 |
| Azithromycin | Azithromycin | 438 | 277 |
| Alprazolam | Alprazolam | 431 | 64 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 419 | 123 |
| Famotidine | Famotidine | 403 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 395 | 119 |
| Ozempic | Semaglutide | 389 | 77 |
| Hydralazine Hcl | Hydralazine Hcl | 377 | 106 |
| Tramadol Hcl | Tramadol Hcl | 371 | 79 |
| Clonazepam | Clonazepam | 326 | 45 |
| Montelukast Sodium | Montelukast Sodium | 326 | 94 |
| Lisinopril | Lisinopril | 318 | 88 |
| Trazodone Hcl | Trazodone Hcl | 313 | 79 |
| Potassium Chloride | Potassium Chloride | 305 | 92 |
| Losartan Potassium | Losartan Potassium | 304 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 89 |
| Furosemide | Furosemide | 290 | 101 |
| Omeprazole | Omeprazole | 282 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 259 | 63 |
| Sertraline Hcl | Sertraline Hcl | 256 | 75 |
| Ezetimibe | Ezetimibe | 252 | 75 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 252 | 92 |
| Metformin Hcl Er | Metformin Hcl | 248 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 136 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 61 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 231 | 166 |
| Celecoxib | Celecoxib | 230 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 228 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 55 |
| Eliquis | Apixaban | 214 | 47 |
| Ondansetron Odt | Ondansetron | 208 | 77 |
| Pregabalin | Pregabalin | 207 | 44 |
| Metformin Hcl | Metformin Hcl | 206 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 198 | 65 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 184 | 67 |
| Jardiance | Empagliflozin | 178 | 34 |
| Allopurinol | Allopurinol | 168 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 167 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 48 |
| Simvastatin | Simvastatin | 163 | 45 |
| Mirtazapine | Mirtazapine | 158 | 41 |
| Valsartan | Valsartan | 157 | 45 |
| Farxiga | Dapagliflozin Propanediol | 151 | 34 |
| Alendronate Sodium | Alendronate Sodium | 148 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 40 |
| Methylprednisolone | Methylprednisolone | 144 | 104 |
| Fluconazole | Fluconazole | 143 | 70 |
| Torsemide | Torsemide | 139 | 57 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 138 | 45 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 135 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 128 | 40 |
| Prednisone | Prednisone | 127 | 59 |
| Myrbetriq | Mirabegron | 126 | 35 |
| Methocarbamol | Methocarbamol | 122 | 41 |
| Trulicity | Dulaglutide | 121 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 38 |
| Meloxicam | Meloxicam | 115 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 111 | 35 |
| Glimepiride | Glimepiride | 109 | 32 |
| Trintellix | Vortioxetine Hydrobromide | 103 | 20 |
| Naproxen | Naproxen | 102 | 42 |
| Linzess | Linaclotide | 101 | 35 |
| Colesevelam Hcl | Colesevelam Hcl | 99 | 21 |
| Mupirocin | Mupirocin | 98 | 41 |
| Januvia | Sitagliptin Phosphate | 95 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 29 |
| Lorazepam | Lorazepam | 94 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 50 |
| Donepezil Hcl | Donepezil Hcl | 92 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 48 |
| Buspirone Hcl | Buspirone Hcl | 87 | 25 |
| Promethazine Hcl | Promethazine Hcl | 87 | 32 |
| Temazepam | Temazepam | 86 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 18 |
| Spironolactone | Spironolactone | 84 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 60 |
| Baclofen | Baclofen | 80 | 14 |
| Bupropion Xl | Bupropion Hcl | 80 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 26 |
| Sucralfate | Sucralfate | 78 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 18 |
| Repatha Sureclick | Evolocumab | 76 | 18 |
| Tradjenta | Linagliptin | 76 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 74 | 18 |
| Meclizine Hcl | Meclizine Hcl | 74 | 29 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 69 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 27 |
| Eszopiclone | Eszopiclone | 66 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 64 | 25 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 64 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 17 |
| Cefuroxime | Cefuroxime Axetil | 63 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Clonidine Hcl | Clonidine Hcl | 60 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Ibuprofen | Ibuprofen | 57 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 54 | 13 |
| Atenolol | Atenolol | 52 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 52 | 17 |
| Topiramate | Topiramate | 50 | 11 |
| Diazepam | Diazepam | 49 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | 13 |
| Chlorthalidone | Chlorthalidone | 48 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 42 |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 28 |
| Raloxifene Hcl | Raloxifene Hcl | 48 | 16 |
| Verapamil Er | Verapamil Hcl | 48 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 17 |
| Levofloxacin | Levofloxacin | 47 | 42 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | 11 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 44 | suppressed |
| Telmisartan | Telmisartan | 42 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | 13 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 13 |
| Nystatin | Nystatin | 29 | 17 |
| Azelastine Hcl | Azelastine Hcl | 28 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Colchicine | Colchicine | 23 | 11 |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 13 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | 11 |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.49 · 16 records | Corcept Therapeutics | AREXVY, CAPLYTA, Dexcom G6 Transmitter, IBSRELA, Kerendia, Korlym, OTEZLA, Ozempic, REPATHA, SHINGRIX, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error